ALTEA ANNOUNCES POSITIVE DATA ON INSULIN PATCH

Altea Therapeutics has announced positive results from Phase I human clinical studies of its basal insulin transdermal patch showing efficient, sustained and constant delivery of insulin at therapeutic levels.

In a glucose-clamp study in normal subjects, Altea achieved constant insulin delivery at therapeutic levels over a 12-hour patch application period. The data show efficient delivery of the applied dose of insulin and demonstrate favorable pharmacodynamics of transdermal insulin delivery when compared to a subcutaneous injection of a long-acting insulin analog. The company is developing both 12- and 24-hour transdermal patches based on its proprietary PassPort System to provide constant basal levels of insulin for people with Type 1 or Type 2 diabetes.

"These findings are very important to our clinical development program as they confirm efficient and constant delivery of basal insulin from our PassPort Patch," Eric Tomlinson, president and CEO of Altea, said. "These results give us confidence that basal insulin transdermal patches can be a cost-effective alternative for people currently using insulin injections to manage their diabetes. A higher patient acceptance of a basal insulin transdermal patch over needle injections enables physicians to start subjects earlier on insulin in the management of Type 1 and Type 2 diabetes."